HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Morrow, D. A. Articles by Cannon, C. P. Search for Related Content PubMed PubMed Citation Articles by Morrow, D. A. Articles by Cannon, C. P. Related Collections Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes

¹ Department of Medicine and TIMI Study Group, Brigham & Women’s Hospital, 75 Francis St., Boston, MA 02115

² Children’s Hospital Medical Center, 300 Longwood Ave., Boston, MA 02115

³ Donald W. Reynolds Cardiovascular Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., CS 7.142, Dallas, TX 75390-9047

^aaddress correspondence to this author at: Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115; fax 617-734-7329, e-mail dmorrow@partners.org

The first 300 words of the full text of this article appear below.

Effective risk assessment guides appropriate triage and therapy for patients with suspected unstable angina or non-ST-elevation myocardial infarction (MI) (1)(2). Cardiac biomarkers play a valuable role in risk stratification in non-ST-elevation acute coronary syndromes (NSTE ACS). In particular, the cardiac troponins have been identified as the preferred biomarkers for this purpose (1). Clinical application of cardiac troponin I (cTnI) has been complicated by a lack of standardization across the multiple commercially available assays, which has produced substantial variation in the reported clinical decision limits. As such, clinical appraisal of the prognostic performance of each cTnI assay is important to providing an evidence-based guide to its use for risk assessment.

The most recent generation cTnI assay from Beckman Coulter (AccuTnI^TM) uses antibodies directed at a stable region (amino acids 30–110) of the NH₂ terminus of cTnI and delivers very good analytic performance (3)(4). We evaluated this assay for the assessment of the short-term risk of death and recurrent ischemic events among patients with suspected NSTE ACS enrolled in the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS)-Thrombolysis in Myocardial Infarction (TIMI) 16 trial.

OPUS-TIMI 16 was a multicenter, randomized, parallel-group trial comparing an oral glycoprotein IIb/IIIa inhbitor with placebo for patients with ACS. The design and results of OPUS-TIMI 16 have been reported (5). The protocol was approved by the Institutional Review Board of each participating hospital, and all patients signed written informed consent. Patients were included if they presented within 72 h of symptom onset and had at least one of the following: dynamic electrocardiographic changes; increased cardiac markers; history of coronary artery disease; or age 65 with diabetes or vascular disease. Patients were randomized to placebo or one of two orbofiban doses. The present substudy was . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				P. Venge, S. James, L. Jansson, and B. Lindahl Clinical Performance of Two Highly Sensitive Cardiac Troponin I Assays Clin. Chem., January 1, 2009; 55(1): 109 - 116. [Abstract] [Full Text] [PDF]

				J. R Tate, W. Ferguson, R. Bais, K. Kostner, T. Marwick, and A. Carter The determination of the 99th centile level for troponin assays in an Australian reference population Ann Clin Biochem, May 1, 2008; 45(3): 275 - 288. [Abstract] [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]

				P. A. Kavsak, A. R. MacRae, G. E. Palomaki, A. M. Newman, D. T. Ko, V. Lustig, J. V. Tu, and A. S. Jaffe Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Naive Emergency Department Patients Clin. Chem., November 1, 2006; 52(11): 2028 - 2035. [Abstract] [Full Text] [PDF]

				L Keating, J R Benger, R Beetham, S Bateman, S Veysey, J Kendall, and R Pullinger The PRIMA Study: presentation ischaemia-modified albumin in the emergency department. Emerg. Med. J., October 1, 2006; 23(10): 764 - 768. [Abstract] [Full Text] [PDF]

				K A A Fox, J Birkhead, R Wilcox, C Knight, and J Barth British Cardiac Society Working Group on the definition of myocardial infarction Heart, June 1, 2004; 90(6): 603 - 609. [Abstract] [Full Text] [PDF]